Received the GIANTS OF MS AWARD in Research, a lifetime achievement award. Hard to believe the years have passed, but still going strong with exciting work on nasal anti-CD3 for progressive MS, MS immunology and the microbiome. Here’s a link to my remarks: https://t.co/WgNEvwYwgZ
Check out our new paper on Progression Independent of Relapse Activity (PIRA) in NMOSD, MOGAD and MS!
Special thanks to my incredible mentor, Dr. @mlevy18 , and to my colleagues for their valuable collaboration!
@Gauruv@MGHNeurology@BWHNeurology
https://t.co/h7J7QPzo8X
Can we predict contrast+ lesions in #MultipleSclerosis using serum neurofilament #NfL? Best performance in <50 years, for NfL >23.0 pg/mL (sens 25%, spec 95%) or 30.8% increase (sens 52%, spec 81%).
Study from @Gauruv@MassGenBrigham@harvardmed ▶️ https://t.co/eXzLGjxM5u
@phil_bilodeau@shamik_b@AlexMuccilli Great approach @phil_bilodeau! I also screen for nutritional deficiencies, Lupus, Sjogrens and infection (HIV syphilis Lyme bartonella), and much less common but several paraneoplastic Abs (CRMP5) have also been associated. Excited for Ravulizumab availability🤞🏾
Today we said goodbye to Dr. @Gauruv Bose, our neuroimmunology clinical fellow in @MassGenBrigham! He is not only a great neurologist, but also a wonderful human being! Diligent, committed and professional!
Goodluck @Gauruv! You definitely deserve the bests!
@NegarMowlazadeh@MassGenBrigham Thank you for this send-off @NegarMowlazadeh ! I really enjoyed getting to meet you and working with you — you have a bright future, don’t forget about me when you become a leader in the field!
Impressive study from @BrighamWomens@bmj_latest : double blind #RCT of over 25000 people showing #VitaminD 2000iu daily reduced #autoimmune diseases by 22% over 5 years, not bad for a safe vitamin that many are deficient in! #VITAL
https://t.co/qoLwWOpD8d
Tanuja Chitnis, M.D. has been named the department’s first Associate Chair for Clinical Trials. Dr. Chitnis is the Cindy Larsen Chugg Distinguished Chair in Neurology at BWH and Professor of Neurology, Harvard Medical School. Congratulations, Tanuja!
#BWHNeurology#BWH
This is it- 10 million adults, 20y follow-up. 801 dx w/MS VS 1500+ controls: EBV seroconversion occurred in ALL who developed MS, except 1. We have the target—let’s fund the treatment! @ScienceMagazine@HarvardChanSPH@mssociety @MSSocietyCanada
https://t.co/A5FNZ6pQOM
Brigham and Women’s Hospital is set to begin a clinical trial that will test the safety and efficacy of a new vaccine delivered nasally intended to prevent and slow the progression of Alzheimer’s disease.